Finance

Lists
ATRC:NASDAQ
AtriCure Inc
$39.49
+0.38%
(+0.15) 1D
$39.49
0.00% (0.00)
After hours
Closed: Aug 6, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ATRC...
Open
$39.55
High
$40.48
Low
$39.00
Mkt. cap
2.01B
Avg. vol.
0.00
Volume
762.18K
P/E ratio
182.41
52-wk high
$43.18
52-wk low
$25.37
EPS
$0.22
Beta
1.20
Shares outstanding
50.87M
No. of employees
1K
Open
$39.55
High
$40.48
Low
$39.00
Mkt. cap
2.01B
Avg. vol.
0.00
Volume
762.18K
P/E ratio
182.41
52-wk high
$43.18
52-wk low
$25.37
EPS
$0.22
Beta
1.20
Shares outstanding
50.87M
No. of employees
1K
About AtriCure Inc
CEOMichael H Carrel | Michael H Carrel
Employees1.35K
FoundedNov 2000
HeadquartersMason, Ohio, United States
SectorMedical device
Websiteatricure.com
Analyst ratings
Based on 8 analysts giving stock ratings to ATRC in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ATRC in the last 3 months.
Highest
Current $39.49
$55.00 (+39.28%)
Average
$47.29 (+19.75%)
Lowest
$36.00 (-8.84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Priya Sachdeva
UBS
Buy
Reiterated
$50.00
+26.6%
07/28/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
$55.00
+39.3%
07/23/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$50.00
+26.6%
07/24/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$50.00
+26.6%
07/24/2026
Marie Thibault
BTIG
Buy
Reiterated
$45.00
+14%
07/24/2026
Michael Matson
Needham
Buy
Reiterated
$45.00
+14%
07/24/2026
Lilia-Celine (Lily) Lozada
J.P. Morgan
Hold
Maintained
$36.00
-8.8%
07/24/2026
Danielle Antalffy
UBS
Buy
Maintained
$55.00
+39.3%
02/18/2026
Daniel Stauder
Citizens JMP
Buy
Maintained
$52.00
+31.7%
02/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
134.27M
140.50M
141.25M
153.60M
Cost of goods sold
32.94M
35.16M
31.94M
34.98M
Cost of revenue
32.94M
35.16M
31.94M
34.98M
Research and development expenses
22.89M
24.50M
24.24M
26.40M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
78.23M
78.34M
84.55M
82.56M
Operating expense
101.12M
102.85M
108.78M
108.96M
Total operating expenses
134.06M
138.01M
140.72M
143.94M
Operating income
208.00K
2.49M
526.00K
9.66M
Other non operating income
9.00K
-641.00K
-37.00K
-100.00K
EBT including unusual items
-86.00K
2.36M
394.00K
9.43M
EBT excluding unusual items
-86.00K
2.36M
394.00K
9.43M
Income tax expense
181.00K
604.00K
286.00K
471.00K
Effective tax rate
-210.47%
25.59%
72.59%
5.00%
Other operating expenses
-
-
-
-
Net income
-267.00K
1.76M
108.00K
8.96M
Net profit margin
-0.20%
1.25%
0.08%
5.83%
Earnings per share
-0.01
0.06
-
0.18
Interest and investment income
1.16M
1.33M
1.24M
1.18M
Interest expense
-1.47M
-1.50M
-1.34M
-1.32M
Net interest expenses
-303.00K
-173.00K
-95.00K
-139.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
5.38M
7.60M
5.80M
14.97M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps